Trial site
The Second People's Hospital of Neijiang
Neijiang, 641000, ChinaNot linked to an institution yet
- 15running trials
- 5closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 25 trials
- Phase 2/33 trials
- Status
- Active, not recruiting8 trials
- Recruiting6 trials
- Completed4 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Daiichi Sankyo2 trials
- Shanghai Pharmaceuticals Holding Co., Ltd2 trials
- TJ Biopharma Co., Ltd.2 trials
- 3D Medicines (Sichuan) Co., Ltd.1 trial
- Beijing Tiantan Hospital1 trial
- and 12 more
Running trials
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336· Phase 2· TJ Biopharma Co., Ltd.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Yu Liu, Site 0424
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yu Liu, Master
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source
Contact: Xujuan Wang
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Xujuan Wang
Recruiting
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
NCT05872347· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Xujuan Wang
Recruiting
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05860465· Phase 2/3· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Xujuan Wang
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
KN035 for dMMR/MSI-H Advanced Solid Tumors
NCT03667170· Phase 2· 3D Medicines (Sichuan) Co., Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error